Cargando…

Case Report: MR-Guided Adaptive Radiotherapy, Some Room to Maneuver

BACKGROUND: A magnetic resonance linear accelerator (MR-Linac) provides superior soft tissue contrast to evaluate inter- and intra-fraction motion and facilitate online adaptive radiation therapy (ART). We present here an unusual case of locally advanced castrate-resistant prostate cancer treated wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Winnie, Winter, Jeff, Padayachee, Jerusha, Dang, Jennifer, Kong, Vickie, Chung, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047540/
https://www.ncbi.nlm.nih.gov/pubmed/35494044
http://dx.doi.org/10.3389/fonc.2022.877452
_version_ 1784695749605326848
author Li, Winnie
Winter, Jeff
Padayachee, Jerusha
Dang, Jennifer
Kong, Vickie
Chung, Peter
author_facet Li, Winnie
Winter, Jeff
Padayachee, Jerusha
Dang, Jennifer
Kong, Vickie
Chung, Peter
author_sort Li, Winnie
collection PubMed
description BACKGROUND: A magnetic resonance linear accelerator (MR-Linac) provides superior soft tissue contrast to evaluate inter- and intra-fraction motion and facilitate online adaptive radiation therapy (ART). We present here an unusual case of locally advanced castrate-resistant prostate cancer treated with high-dose palliative ultra-hypofractionated radiation therapy on the MR-Linac with significant inter-fraction tumor regression. CASE PRESENTATION: The patient was a 65-year-old man diagnosed with metastatic prostate cancer to bone and pelvic lymph nodes 7 years prior. At diagnosis, he presented with a PSA of 23 ng/ml and was commenced on a luteinizing hormone-releasing hormone agonist, achieving a PSA nadir of 4.68 ng/ml at 12 months. The patient subsequently had progressive lower urinary tract symptoms, his PSA increased to 47 ng/ml, and there was a markedly enlarged pelvic mass involving the prostate with gross extra-capsular disease and invasion into the posterior bladder wall. The patient was referred for palliative radiation to the pelvic mass due to urinary symptoms, pain, and lower limb paraesthesia. Treatment was planned to be delivered on the MR-Linac with a schedule of 36 Gy over 6 weekly factions allowing for maximal target dose delivery while minimizing surrounding organs at risk (OARs) radiation exposure. Unexpectedly, the target volume had a marked 49% (453 cc to 233 cc) reduction that was accounted for in the online adaptive process. A new reference plan was generated after 3 fractions to add sacral plexus as an OAR, previously not visible due to mass encroachment. The patient reported ongoing reduction in urinary symptoms, pelvic pain, and lower limb paresthesia by the end of treatment. CONCLUSION: Using daily MR-guided ART, improved visualization of the changing target and OARs ensured safe dose escalation. The unexpected positive response of the target and improved patient outcomes demonstrated the added value of the MR-Linac for online adaptive radiotherapy in this setting.
format Online
Article
Text
id pubmed-9047540
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-90475402022-04-29 Case Report: MR-Guided Adaptive Radiotherapy, Some Room to Maneuver Li, Winnie Winter, Jeff Padayachee, Jerusha Dang, Jennifer Kong, Vickie Chung, Peter Front Oncol Oncology BACKGROUND: A magnetic resonance linear accelerator (MR-Linac) provides superior soft tissue contrast to evaluate inter- and intra-fraction motion and facilitate online adaptive radiation therapy (ART). We present here an unusual case of locally advanced castrate-resistant prostate cancer treated with high-dose palliative ultra-hypofractionated radiation therapy on the MR-Linac with significant inter-fraction tumor regression. CASE PRESENTATION: The patient was a 65-year-old man diagnosed with metastatic prostate cancer to bone and pelvic lymph nodes 7 years prior. At diagnosis, he presented with a PSA of 23 ng/ml and was commenced on a luteinizing hormone-releasing hormone agonist, achieving a PSA nadir of 4.68 ng/ml at 12 months. The patient subsequently had progressive lower urinary tract symptoms, his PSA increased to 47 ng/ml, and there was a markedly enlarged pelvic mass involving the prostate with gross extra-capsular disease and invasion into the posterior bladder wall. The patient was referred for palliative radiation to the pelvic mass due to urinary symptoms, pain, and lower limb paraesthesia. Treatment was planned to be delivered on the MR-Linac with a schedule of 36 Gy over 6 weekly factions allowing for maximal target dose delivery while minimizing surrounding organs at risk (OARs) radiation exposure. Unexpectedly, the target volume had a marked 49% (453 cc to 233 cc) reduction that was accounted for in the online adaptive process. A new reference plan was generated after 3 fractions to add sacral plexus as an OAR, previously not visible due to mass encroachment. The patient reported ongoing reduction in urinary symptoms, pelvic pain, and lower limb paresthesia by the end of treatment. CONCLUSION: Using daily MR-guided ART, improved visualization of the changing target and OARs ensured safe dose escalation. The unexpected positive response of the target and improved patient outcomes demonstrated the added value of the MR-Linac for online adaptive radiotherapy in this setting. Frontiers Media S.A. 2022-04-14 /pmc/articles/PMC9047540/ /pubmed/35494044 http://dx.doi.org/10.3389/fonc.2022.877452 Text en Copyright © 2022 Li, Winter, Padayachee, Dang, Kong and Chung https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Li, Winnie
Winter, Jeff
Padayachee, Jerusha
Dang, Jennifer
Kong, Vickie
Chung, Peter
Case Report: MR-Guided Adaptive Radiotherapy, Some Room to Maneuver
title Case Report: MR-Guided Adaptive Radiotherapy, Some Room to Maneuver
title_full Case Report: MR-Guided Adaptive Radiotherapy, Some Room to Maneuver
title_fullStr Case Report: MR-Guided Adaptive Radiotherapy, Some Room to Maneuver
title_full_unstemmed Case Report: MR-Guided Adaptive Radiotherapy, Some Room to Maneuver
title_short Case Report: MR-Guided Adaptive Radiotherapy, Some Room to Maneuver
title_sort case report: mr-guided adaptive radiotherapy, some room to maneuver
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047540/
https://www.ncbi.nlm.nih.gov/pubmed/35494044
http://dx.doi.org/10.3389/fonc.2022.877452
work_keys_str_mv AT liwinnie casereportmrguidedadaptiveradiotherapysomeroomtomaneuver
AT winterjeff casereportmrguidedadaptiveradiotherapysomeroomtomaneuver
AT padayacheejerusha casereportmrguidedadaptiveradiotherapysomeroomtomaneuver
AT dangjennifer casereportmrguidedadaptiveradiotherapysomeroomtomaneuver
AT kongvickie casereportmrguidedadaptiveradiotherapysomeroomtomaneuver
AT chungpeter casereportmrguidedadaptiveradiotherapysomeroomtomaneuver